FDA Issues Alert on Biaxin Based on Study
The Food and Drug Administration issued an alert Friday involving Biaxin, an antibiotic made by Abbott Laboratories.The agency issued an alert to patients and health care professionals discussing a study done on patients with heart disease in Denmark. Biaxin, known generically as clarithromycin, was associated with a “higher chance of death from heart problems,” the FDA said. The study was published Thursday in the British Medical Journal.
But, the agency also said, it was not recommending any changes to the use of Biaxin based on the study. The FDA said that previous studies of antibacterial drugs and Biaxin have not been associated with an increased risk of death. Biaxin is commonly used to treat bacterial respiratory infections. However, researchers have been studying whether Biaxin and similar drugs might prevent or treat heart disease.
Source: ABC 7 News.
There are currently no comments on this thread.